# Nutex Health Inc.: financial statements, quarterly

NUTX · Nasdaq · CIK 1479681 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nutx.md) · [Financials](/companies/nutx/financials.md) · [Filings](/companies/nutx/filings.md) · [Insiders](/companies/nutx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nutx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [62.7](/filings/0001479681-24-000014.md) | [69.7](/filings/0001479681-25-000006.md) | [67.5](/filings/0001628280-25-052951.md) | [76.1](/filings/0001628280-25-052957.md) | [78.8](/filings/0001628280-25-053166.md) | [258](/filings/0001479681-25-000006.md) | [212](/filings/0001628280-26-028849.md) | [244](/filings/0001628280-26-054268.md) | [268](/filings/0001628280-25-053166.md) | [152 d](/filings/0001628280-26-015168.md) | [216](/filings/0001628280-26-028849.md) | [211](/filings/0001628280-26-054268.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [7.1](/filings/0001479681-24-000014.md) | [13.2](/filings/0001479681-25-000006.md) | [10.2](/filings/0001628280-25-052951.md) | [22.6](/filings/0001628280-25-052957.md) | [21.9](/filings/0001628280-25-053166.md) | [142](/filings/0001479681-25-000006.md) | [118](/filings/0001628280-26-028849.md) | [125](/filings/0001628280-26-054268.md) | [155](/filings/0001628280-25-053166.md) | [46.1 d](/filings/0001628280-26-015168.md) | [91.7](/filings/0001628280-26-028849.md) | [141](/filings/0001628280-26-054268.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.8)](/filings/0001479681-24-000014.md) | [(26.1)](/filings/0001479681-25-000006.md) | [1.5](/filings/0001628280-25-052951.md) | [5.3](/filings/0001628280-25-052957.md) | [9.7](/filings/0001628280-25-053166.md) | [114](/filings/0001479681-25-000006.md) | [80.7](/filings/0001628280-26-028849.md) | [33.7](/filings/0001628280-26-054268.md) | [130](/filings/0001628280-25-053166.md) | [30.9 d](/filings/0001628280-26-015168.md) | [81.3](/filings/0001628280-26-028849.md) | [122](/filings/0001628280-26-054268.md) |
| Interest expense | $m | [4.1](/filings/0001558370-23-018558.md) | [4.2](/filings/0001558370-24-004287.md) | [4.4](/filings/0001558370-24-007414.md) | [5.1](/filings/0001628280-25-052957.md) | [5.4](/filings/0001628280-25-053166.md) | [5.1](/filings/0001479681-25-000006.md) | [6.1](/filings/0001628280-26-028849.md) | [5.7](/filings/0001628280-26-054268.md) | [5.5](/filings/0001628280-25-053166.md) | [5.0 d](/filings/0001628280-26-015168.md) | [4.7](/filings/0001628280-26-028849.md) | [4.7](/filings/0001628280-26-054268.md) |
| Income tax | $m | [(0.3)](/filings/0001479681-24-000014.md) | [(3.0)](/filings/0001479681-25-000006.md) | [0.4](/filings/0001628280-25-052951.md) | [0.9](/filings/0001628280-25-052957.md) | [4.6](/filings/0001628280-25-053166.md) | [8.6](/filings/0001479681-25-000006.md) | [20.4](/filings/0001628280-26-028849.md) | [7.6](/filings/0001628280-26-054268.md) | [27.1](/filings/0001628280-25-053166.md) | [9.3 d](/filings/0001628280-26-015168.md) | [13.8](/filings/0001628280-26-028849.md) | [20.8](/filings/0001628280-26-054268.md) |
| Net income | $m | [(5.5)](/filings/0001479681-24-000014.md) | [(31.6)](/filings/0001479681-25-000006.md) | [(0.4)](/filings/0001628280-25-052951.md) | [(0.4)](/filings/0001628280-25-052957.md) | [(8.8)](/filings/0001628280-25-053166.md) | [61.7](/filings/0001479681-25-000006.md) | [21.2](/filings/0001628280-26-028849.md) | [(17.7)](/filings/0001628280-26-054268.md) | [55.4](/filings/0001628280-25-053166.md) | [11.8 d](/filings/0001628280-26-015168.md) | [46.8](/filings/0001628280-26-028849.md) | [65.8](/filings/0001628280-26-054268.md) |
| Diluted EPS | $ per share | [(1.25)](/filings/0001479681-24-000014.md) | [(7.47)](/filings/0001479681-25-000006.md) | [(0.08)](/filings/0001628280-25-052951.md) | [(0.07)](/filings/0001628280-25-052957.md) | [(1.72)](/filings/0001628280-25-053166.md) | [11.12](/filings/0001479681-25-000006.md) | [3.33](/filings/0001628280-26-028849.md) | [(2.95)](/filings/0001628280-26-054268.md) | [7.76](/filings/0001628280-25-053166.md) | not reported | [6.52](/filings/0001628280-26-028849.md) | [9.38](/filings/0001628280-26-054268.md) |
| Basic EPS | $ per share | [(1.25)](/filings/0001479681-24-000014.md) | [(7.47)](/filings/0001479681-25-000006.md) | [(0.08)](/filings/0001628280-25-052951.md) | [(0.07)](/filings/0001628280-25-052957.md) | [(1.72)](/filings/0001628280-25-053166.md) | [11.83](/filings/0001479681-25-000006.md) | [3.74](/filings/0001628280-26-028849.md) | [(2.95)](/filings/0001628280-26-054268.md) | [8.27](/filings/0001628280-25-053166.md) | not reported | [6.70](/filings/0001628280-26-028849.md) | [9.58](/filings/0001628280-26-054268.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.8](/filings/0001558370-23-018558.md) | [22.0](/filings/0001628280-26-015168.md) | [30.0](/filings/0001558370-24-007414.md) | [40.8](/filings/0001479681-24-000007.md) | [46.9](/filings/0001479681-24-000014.md) | [40.6](/filings/0001628280-26-054268.md) | [84.7](/filings/0001628280-26-028849.md) | [96.7](/filings/0001628280-26-054268.md) | [166](/filings/0001628280-25-053166.md) | [186](/filings/0001628280-26-054268.md) | [207](/filings/0001628280-26-028849.md) | [205](/filings/0001628280-26-054268.md) |
| Current assets | $m | [89.9](/filings/0001558370-23-018558.md) | [90.8](/filings/0001628280-25-052895.md) | [100](/filings/0001558370-24-007414.md) | [114](/filings/0001479681-24-000007.md) | [120](/filings/0001479681-24-000014.md) | [292](/filings/0001628280-26-015168.md) | [402](/filings/0001628280-25-052951.md) | [473](/filings/0001628280-25-052957.md) | [593](/filings/0001628280-25-053166.md) | [539](/filings/0001628280-26-054268.md) | [580](/filings/0001628280-26-028849.md) | [586](/filings/0001628280-26-054268.md) |
| Total assets | $m | [480](/filings/0001558370-23-018558.md) | [398](/filings/0001628280-25-052895.md) | [404](/filings/0001558370-24-007414.md) | [422](/filings/0001479681-24-000007.md) | [438](/filings/0001479681-24-000014.md) | [655](/filings/0001628280-26-015168.md) | [762](/filings/0001628280-25-052951.md) | [841](/filings/0001628280-25-052957.md) | [965](/filings/0001628280-25-053166.md) | [919](/filings/0001628280-26-054268.md) | [957](/filings/0001628280-26-028849.md) | [965](/filings/0001628280-26-054268.md) |
| Current liabilities | $m | [67.3](/filings/0001558370-23-018558.md) | [58.3](/filings/0001628280-25-052895.md) | [59.9](/filings/0001558370-24-007414.md) | [71.7](/filings/0001479681-24-000007.md) | [67.6](/filings/0001479681-24-000014.md) | [154](/filings/0001628280-26-015168.md) | [196](/filings/0001628280-25-052951.md) | [195](/filings/0001628280-25-052957.md) | [185](/filings/0001628280-25-053166.md) | [158](/filings/0001628280-26-054268.md) | [184](/filings/0001628280-26-028849.md) | [117](/filings/0001628280-26-054268.md) |
| Total liabilities | $m | [375](/filings/0001558370-23-018558.md) | [319](/filings/0001628280-25-052895.md) | [324](/filings/0001558370-24-007414.md) | [340](/filings/0001479681-24-000007.md) | [359](/filings/0001479681-24-000014.md) | [467](/filings/0001628280-26-015168.md) | [507](/filings/0001628280-25-052951.md) | [504](/filings/0001628280-25-052957.md) | [526](/filings/0001628280-25-053166.md) | [495](/filings/0001628280-26-054268.md) | [515](/filings/0001628280-26-028849.md) | [457](/filings/0001628280-26-054268.md) |
| Long-term debt | $m | [19.3](/filings/0001558370-23-018558.md) | [26.3](/filings/0001628280-25-052895.md) | [26.3](/filings/0001558370-24-007414.md) | [22.4](/filings/0001479681-24-000007.md) | [26.8](/filings/0001479681-24-000014.md) | [22.5](/filings/0001628280-26-015168.md) | [21.7](/filings/0001628280-25-052951.md) | [20.5](/filings/0001628280-25-052957.md) | [25.6](/filings/0001628280-25-053166.md) | [29.2](/filings/0001628280-26-054268.md) | [24.3](/filings/0001628280-26-028849.md) | [31.1](/filings/0001628280-26-054268.md) |
| Current portion of debt | $m | [19.6](/filings/0001558370-23-018558.md) | [10.8](/filings/0001628280-25-052895.md) | [9.4](/filings/0001558370-24-007414.md) | [14.2](/filings/0001479681-24-000007.md) | [10.5](/filings/0001479681-24-000014.md) | [14.4](/filings/0001628280-26-015168.md) | [13.6](/filings/0001628280-25-052951.md) | [19.0](/filings/0001628280-25-052957.md) | [18.0](/filings/0001628280-25-053166.md) | [13.3](/filings/0001628280-26-054268.md) | [16.7](/filings/0001628280-26-028849.md) | [8.5](/filings/0001628280-26-054268.md) |
| Shareholders' equity | $m | [89.9](/filings/0001558370-23-018558.md) | [61.5](/filings/0001628280-25-052895.md) | [63.0](/filings/0001558370-24-007414.md) | [62.7](/filings/0001479681-24-000007.md) | [60.4](/filings/0001479681-24-000014.md) | [132](/filings/0001628280-26-015168.md) | [177](/filings/0001628280-25-052951.md) | [235](/filings/0001628280-25-052957.md) | [317](/filings/0001628280-25-053166.md) | [329](/filings/0001628280-26-054268.md) | [346](/filings/0001628280-26-028849.md) | [394](/filings/0001628280-26-054268.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2.0 d](/filings/0001479681-24-000014.md) | [(1.8) d](/filings/0001628280-26-015168.md) | [3.1](/filings/0001628280-25-052951.md) | [13.3 d](/filings/0001628280-25-052957.md) | [6.8 d](/filings/0001628280-25-053166.md) | [0.1 d](/filings/0001628280-26-015168.md) | [51.0](/filings/0001628280-26-028849.md) | [27.3 d](/filings/0001628280-26-054268.md) | [99.5 d](/filings/0001628280-25-053166.md) | [70.4 d](/filings/0001628280-26-015168.md) | [75.5](/filings/0001628280-26-028849.md) | [34.2 d](/filings/0001628280-26-054268.md) |
| Capital expenditure | $m | not reported | not reported | [0.7](/filings/0001628280-25-052951.md) | [0.6 d](/filings/0001628280-25-052957.md) | [0.6 d](/filings/0001628280-25-053166.md) | [0.4 d](/filings/0001628280-26-015168.md) | [0.1](/filings/0001628280-26-028849.md) | [0.8 d](/filings/0001628280-26-054268.md) | [0.3 d](/filings/0001628280-25-053166.md) | [1.4 d](/filings/0001628280-26-015168.md) | [1.2](/filings/0001628280-26-028849.md) | [2.5 d](/filings/0001628280-26-054268.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-028849.md) | [0.0 d](/filings/0001628280-26-054268.md) | not reported | not reported | [31.7](/filings/0001628280-26-028849.md) | [19.0 d](/filings/0001628280-26-054268.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [655](/filings/0001607062-22-000727.md) | [43.4](/filings/0001558370-24-007414.md) | [657](/filings/0001558370-23-014212.md) | [4.4](/filings/0001479681-24-000014.md) | [4.8](/filings/0001628280-25-052951.md) | [5.0](/filings/0001628280-25-052957.md) | [5.1](/filings/0001628280-25-053166.md) | [6.5](/filings/0001628280-26-028849.md) | [6.0](/filings/0001628280-26-054268.md) | [7.2](/filings/0001628280-25-053166.md) | [7.2](/filings/0001628280-26-028849.md) | [7.0](/filings/0001628280-26-054268.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,847,973 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054268.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.